Cancer Biomarkers and Precision Medicine

From 2019 to 2020, cancer mortality declined by 1.5%, contributing to a 33% overall reduction in cancer deaths in the United States. This progress reflects decades of improvement in early detection, treatment advances and a growing understanding of cancer biology. 

Biomarker discovery has played an important role in this shift, supporting the move toward more personalized cancer care. Understanding how these tools fit into clinical care and the challenges that limit their broader use can help clinicians better navigate an increasingly complex oncology landscape.

Key Takeaways

• Cancer biomarkers play different oncological roles, from detecting cancer to guiding treatment and monitoring responses.
• Diagnostic and prognostic biomarkers help with identification, staging and understanding expected outcomes, independent of treatment choice.
• Predictive and pharmacodynamic biomarkers support treatment selection and assess therapy effectiveness.
• Despite extensive research, many biomarkers do not reach routine clinical use due to various challenges.
• Advancing precision medicine requires more than pharmacological innovation. It depends on standardized workflows, usable data and coordination. 

Types of Cancer Biomarkers

Cancer biomarkers serve distinct but complementary roles across the continuum of care, from detection to treatment response. 

• Diagnostic biomarkers: Detect or confirm the presence of cancer. In some cases, they help determine the tumor’s molecular subtype. 
• Prognostic biomarkers (disease‑related): Provide information about the natural course of cancer.
• Predictive biomarkers (drug‑related): Identify patients most likely to benefit from targeted therapies while anticipating response and toxicity.
• Pharmacodynamic biomarkers: Measure biological changes that occur in response to therapy.

Challenges in Biomarker Development

Despite rapid growth in biomarker research, only a limited number of cancer biomarkers have been successfully developed for routine clinical use. 

Small sample sizes, poor matching between cases and controls and variability in specimen handling can undermine reproducibility and clinical relevance. Additional challenges include:

• Study design
• Biological complexity
• Clinical standardization
• Assay reliability
• Operational quality

Paving the Way for Precision Medicine

Precision medicine extends well beyond biomarkers, targeted therapies and pharmaceutical innovation. Its success depends on an integrated ecosystem that ensures scientific advances translate into real‑world clinical impact. Reliable testing, standardized workflows and accessible, interpretable data are essential to moving precision medicine from promise to practice. 

Without these foundational elements, even the most advanced biomarkers risk limited adoption or inconsistent clinical utility. 

Key enablers to advancing precision medicine include:

• Reliable testing
• Standardized workflows
• Actionable data
• Clinical integration
• Interdisciplinary coordination

Bridging Discovery and Clinical Care

Future progress in precision medicine depends on closing the gap between scientific discovery and everyday clinical practice. As the burden of cancer persists, biomarkers and targeted therapies offer meaningful opportunity. 

Primary care clinicians play a critical role in this transition by supporting appropriate testing, care coordination and informed patient discussions. The question is not whether precision medicine will advance, but whether our clinical systems are prepared to support its role in sustaining declines in cancer mortality.

Resources 

“Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations.” NIH: National Library of Medicine, 2024.

Physician Outreach and Connections

Our growth and outreach liaisons provide support and information to referring physicians and other healthcare providers.